US Biopharmaceutical Third-party Logistics Market Size, Demand, and Trends Analysis 2035

U.S. Biopharmaceutical Third-party Logistics Market Size, Outlook Strategic and AI Adoption

The U.S. biopharmaceutical third-party logistics market size is calculated at USD 61.08 billion in 2025, grew to USD 65.72 billion in 2026, and is projected to reach around USD 127.06 billion by 2035. The market is expanding at a CAGR of 7.6% between 2026 and 2035.

Key Takeaways

• U.S. Biopharmaceutical Third-party Logistics industry poised to reach USD 61.08 billion in 2025.
• Forecasted to grow to USD 127.06 billion by 2035.
• Expected to maintain a CAGR of 7.6% from 2026 to 2035.
• The global biopharmaceutical 3PL market is expected to grow from $152.93 billion in 2025 to $276.24 billion by 2034.
• By supply chain, the non-cold logistics segment led the market share in 2024.
• By supply chain, the cold chain logistics segment is predicted to grow at the fastest rate in the market during the projected timeframe.
• By service type, the warehousing and storage segment dominated the market in 2024.
• By service type, the transportation segment is anticipated to grow at the fastest rate during the forecast period.

Key Metrics and Overview

U.S. Biopharmaceutical Third-Party Logistics Market Size: Robust Distribution Network & Biosimilar Launches

Biopharmaceutical third-party logistics (3PL) entailed the outsourcing of logistic services such as warehousing, transportation, and distribution for pharmaceutical and biopharmaceutical products. These 3PL contributors assist companies in overcoming the difficulties of dispensing conscious products, generally involving specialized infrastructure, including cold chain logistics and real-time tracking to assure compliance with regulations. Mainly, the growth of the market is impelled by outsourcing logistics, in which the target would be a robust distribution network, and an increase in biosimilar launches. Moreover, the rising demand for biosimilar and specialty drugs, which need certain conditions like temperature control, has raised the demand for advanced cold-chain logistics solutions.

The U.S. biopharmaceutical third-party logistics market supports the storage, transportation, and distribution of temperature-sensitive medicines, biologics, vaccines, and specialty therapies. Growing demand for cold chain logistics and advanced tracking technologies is shaping market trends. Companies are investing in automation, digital monitoring, and real-time shipment visibility to improve efficiency and product safety. The competitive landscape includes established logistics providers expanding specialized healthcare services through partnerships, facility upgrades, and technology investments. Rising production of biologics, cell and gene therapies, and personalized medicines is creating new growth opportunities. Increasing regulatory requirements for product quality and secure distribution are encouraging innovation in packaging, warehousing, transportation, and supply chain management across the U.S.

Market Trends and Future Outlook

Growing Demand for Cold Chain Logistics

The demand for temperature-controlled logistics is increasing as biologics, vaccines, and specialty medicines become more common. Logistics providers are expanding cold storage facilities and using advanced monitoring systems. Future investments in reliable cold chain networks will improve product safety, support faster deliveries, and strengthen pharmaceutical supply chains across the United States.

Digital Technologies Improving Operations

Companies are adopting automation, artificial intelligence, and real-time tracking to improve logistics performance. Digital platforms help monitor shipments, reduce delays, and maintain product quality. Future technology upgrades will increase operational efficiency, improve supply chain visibility, and support better decision-making for pharmaceutical manufacturers, healthcare providers, and logistics companies.

Expansion of Specialized Logistics Services

Third-party logistics providers are expanding specialized services for cell therapies, gene therapies, and personalized medicines. Companies are investing in advanced packaging, secure transportation, and regulatory compliance solutions. Future demand for complex biopharmaceutical products will create new business opportunities and encourage continuous innovation in healthcare logistics services across the United States.

Porter’s Five Forces Analysis

• Threat of New Entrants: Low because strict regulations, high capital investment, and specialized cold chain infrastructure create strong barriers for new companies entering the market.
• Bargaining Power of Suppliers: Moderate, as logistics providers depend on packaging, transportation, and technology suppliers. Multiple supplier options reduce dependence, although specialized equipment increases supplier influence.
• Bargaining Power of Buyers: High because pharmaceutical companies demand reliable, compliant, and cost-effective logistics services. Large customers negotiate better pricing, service quality, and delivery terms.
• Threat of Substitutes: Low since specialized third-party logistics providers offer temperature-controlled transportation, regulatory compliance, and secure distribution that standard logistics companies cannot easily replace.
• Competitive Rivalry: High because established companies compete through technology, service quality, nationwide coverage, strategic partnerships, automation, infrastructure expansion, and continuous innovation to attract pharmaceutical and biotechnology customers.

U.S. Biopharmaceutical Third-Party Logistics Market Size Trends

• In January 2025, KeyMed, a rising biopharmaceutical company, made a partnership with US-based biotech Prolium for advancement development in bispecific antibody, including ICP-B02, a CD20×CD3. (Source - Pharmaceutical Technology)
• In May 2024, McKesson’s third-party logistics created a pillar to biopharma companies of all sizes, which assists in operating licensing needs and business progression organizing to tracking programming, and substantially more. (Source - MCKESSON)

Market Data & Statistics

• In 2024, the U.S. exported $5.56 billion of human vaccines and similar products, mainly to the Netherlands, Belgium, Canada, Singapore, and China.
• In 2024, the U.S. imported $9.34 billion of human vaccines and similar products from Ireland, Belgium, Italy, Canada, and Germany.
• Cellares, a U.S.-based biopharma firm, invested $255 million for the launch of an 118,000-square-foot development and commercial-scale manufacturing facility in New Jersey. The facility will be able to produce 40,000 cell-therapy batches annually.
• There were 7,763 clinical trials registered on the clinicaltrials.gov website related to monoclonal antibodies in the U.S.

How Can AI Upgrade the U.S. Biopharmaceutical Third-Party Logistics Market?

AI has a major role in biopharmaceutical third-party logistics (3PL), as it supports in enhancement of efficiency, minimization of risk, and accelerates compliance all over the supply chain. It improves the shipping routing, minimizes the transit frequency, and also reduces the transportation expenses. Furthermore, AI-powered predictive analytics can forecast possible disturbances, like weather events or supply chain congestions. AI can guide in the precise tracking of temperature and other conditions to confirm the product's efficiency and integrity.

Market Dynamics

Driver

Escalating Complexities and Yield of Biopharmaceutical Products

The U.S. biopharmaceutical third-party logistics market is particularly influenced by rising complexities and yield of biopharmaceuticals such as monoclonal antibodies and gene therapies, and branded drugs need particular storage, handling, and transportation requirements, oftentimes comprising temperature-sensitive cold chain logistics. However, 3PL provides the validated logistics, including data loggers, 24/7 tracking, and firm transit services.

Restraint

Accelerated Capital Expenditure and Regulatory Conformity

The primary challenges for the U.S. biopharmaceutical third-party logistics market that are being experienced are increasing capital expenditure, including developing and controlling GDP-compliant facilities, temperature-controlled fleets, validated IT systems, and securing mandatory certifications require significant capital investment and compliance with regulations such as Drug Supply Chain Security Act (DSCSA) and Good Distribution Practice (GDP).

Opportunity

Rising Advances for Temperature-Sensitive Products and Demand for Biologics and Specialty Drugs

In the U.S. biopharmaceutical third-party logistics market, growing demand for biologics and specialty drugs, and boosting advancements for temperature-sensitive products, such as advanced cold-chain solutions, which provide temperature-controlled storage, transportation, and real-time operating, are necessary for regulating the integrity of biopharmaceutical products. Also, the AI-aided and IoT are modifying logistics processes with automation, resulting in more effective and reasonable solutions.

Segmental Insights

Supply Chain Insights

Which Supply Chain Segment Led the Market?

By supply chain, the non-cold logistics segment led the market in 2024. The growing significant demand for biopharmaceutical products, such as various generics and over-the-counter drugs (OTC), can be stored and transported at room temperature, which enables to use of non-cold logistics, a more reasonable and accessible solution. As well as, it raises the expansion of distribution networks of numerous pharmaceutical companies.

The Cold Chain Logistics Segment: Fastest Growing Rate

By supply chain, the cold chain logistics segment is predicted to grow at the fastest rate in the market during the projected timeframe. In the U.S. biopharmaceutical third-party logistics market, biopharmaceutical companies ' demanding for precise temperature control, particularly for vaccines, monoclonal antibodies, and other biologics, is impacting the cold chain logistics solution. Moreover, the vital portion is global vaccine distribution, which is leading to the growth of this segment.

Service Type Insights

How the Warehousing & Storage Segment Dominated the Market?

By service type, the warehousing and storage segment dominated the market in 2024. Regulatory authorities like the FDA in the U.S. and the EMA in Europe possess rigorous guidelines for the storage and distribution of biologics and vaccines. Basically, these products require stringent temperature control systems and specific storage conditions to maintain their efficacy and safety. This segment is highly influenced by advancements in drug development, specifically in oncology, immunology, and infectious diseases.

The Transportation Segment: Fastest Growing

By service type, the transportation segment is anticipated to grow at the fastest rate during the forecast period. Pharmaceutical industries are accelerating the outsourcing of logistics to improve their distribution networks and targets on elemental competencies like research and development. However, the expansion of the biopharmaceutical market and increasing biosimilar launches require efficient transportation and storage conditions as well.

Regional Insights

The U.S. biopharmaceutical third-party logistics market, significantly impacted by the rising development of biologics and specialty drugs, which oftentimes need firm, temperature-controlled systems, which demand advanced cold-chain logistic solutions. Also, the automation, AI integration, and IoT programming are leading factors for the growth of the market. Technologies such as blockchain are widely employed to ensure data accuracy and discoverability over the chain, particularly in temperature-sensitive products like biologics.

For instance,

• In April 2025, UPS Healthcare proposed its global offerings in network healthcare logistics by acquiring Andlauer Healthcare Group (AHG), a Canada-based supply chain management company focused on the healthcare sector. (Source - PYMNTS)

Global Biopharmaceutical Third-Party Logistics Market Growth

The global biopharmaceutical third-party logistics (3PL) market is on a growth path, valued at $143.44 billion in 2024, expected to rise to $152.93 billion in 2025, and projected to reach approximately $276.24 billion by 2034.

Top Companies in the U.S. Biopharmaceutical Third-Party Logistics Market

• UPS Healthcare
• Cardinal Health
• KUEHNE + NAGEL
• AmerisourceBergen Corp.
• McKesson Corporation
• Thermo Fisher Scientific
• DHL International GmbH
• DB Schenker
• Kerry Logistics Network Ltd.
• CEVA Logistics
• Agility Logistics
• SF Express
• XPO Logistics
• Cencora, Inc.
• EVERSANA

Latest Announcement by Industry Leader

• In March 2025, PharmAla Biotech Holdings Inc., a company based on biotechnology research and development and production of novel MDXX class molecules (including its LaNeo™ MDMA), announced about agreement with a third-party logistics company specializing in pharmaceutical products to operate as its US clinical trial distribution associate. Nicholas Kadysh, CEO, PharmAla Biotech, replied that PharmAla has noted in the last few months that US-Canada cross-border shipping unpredictability has increased, which is negatively impacting their many clinical trial customers in the US, which is being optimized by the imposition of tariff hurdles. (Source - GlobeNewswire)
• In December 2024, Knipper Health, Inc., a major supplier of end-to-end pharmaceutical healthcare marketing services and solutions in the U.S., providing the biopharmaceutical and medical industries, announced that the company has acquired the assets of Patheon Pharma Services' sample and fulfillment services from Thermo Fisher Scientific. Michael Laferrera, CEO of Knipper Health, said that they are consistently putting the needs of customers at the forefront and are thrilled to ensure commercial sample customers. (Source - businesswire)

What are the Recent Developments in the U.S. Biopharmaceutical Third-Party Logistics Market?

• In October 2025, Orsini introduced a combined specialty pharmacy and third-party logistics (3PL) service operated out of its new facility in Columbus, Ohio. This rollout broadens the company's national footprint and improves its comprehensive services for biopharmaceutical companies introducing new treatments for rare diseases.
• In April 2025, Eversana, a global supplier of commercial services to the life sciences industry, is developing its pharmaceutical third-party logistics (3PL) services to meet rising client demand. (Source - CONTRACT PHARMA)
• In October 2024, McKesson launched InspiroGene, a devoted business to lead and assist the commercialization of cell and gene therapies. (Source - businesswire)

Segments Covered in the Report

By Supply Chain

• Cold Chain Logistics
• Non-cold Chain Logistics

By Service Type

• Warehousing and Storage
• Transportation
  • Air Freight
  • Sea Freight
  • Overland
• Other Services